In July, 2003, Capex opted to proceed with the conversion of its convertible debenture of $2,000,000 maturing on January 15, 2007. As per the initial Agreement with Capex, the debenture was converted at discount of 15% to the market price. As a result, including accrued interest, our Company issued to Capex a total of 3,910,120 restricted shares of its common stock.
In July and August, our Company granted 137,000 options at an exercise price of $0.00001 per common share to different consultants in lieu of a cash payment. These vested options were immediately exercised.
In August and September, the Company issued 1,610,910 restricted shares of its common stock under a private placement of Units priced at $0.55 per Unit. Each Unit includes one common share and one common share purchase warrant enabling the holder to purchase one additional common share at price of $1.00 for a period of two years. At the option of the Company, the common share purchase warrant may be redeemed upon a 30-day notice to the holder. As part of this issue, the Promissory Note of $500,000 held by Capex was redeemed for a total of 909,091 Units. Subsequent to September 30, 2003, the Company issued a further 909,091 Units under the same terms and conditions to raise an additional $500,000 bringing total proceeds from the private placement to $1,386,000, including the conversion of a promissory note of $500,000 held by Capex.
As of September 30, 2003, the Company's principal capital resources had been acquired through a combination of short and long term debt, and the issuance of our common stock. The Company does not have a credit line available at any banks at this time. Our ability to emerge from our current development stage with respect to our planned business activity is dependent upon our successful efforts to commercialize our current and future products, thus attaining profitable business operations, and/or to raise additional equity financing. Until our Company is able to generate sufficient cash flow to sustain its on going business activity, management plans to seek additional capital through a private placement of its common stock. In the interim, the Company expects to fund itself in the next twelve months from operations, from the issuance of its common stock and/or loans from shareholders or Directors. There is no guarantee that the Company will be able to complete any of the above objectives.
On September 30, 2003, we had negative working capital of ($80,056) compared to a negative working capital of ($828,127) at June 30, 2003. The improvement in working capital was due to our recent equity financing and the conversion of the promissory note of $500,000 held by Capex.
As part of interim financing provided by shareholders, directors and officers, the Company has purchased management services from Capex, the vendor of the C-Chip technology. From time to time, Capex also pays directly certain operations expenses directly and provides funds for working capital to our Company. The amounts due to Capex are non-interest bearing, unsecured, and have no fixed terms of repayment. At September 30, 2003, the amount due to Capex was $210,249 compared to $193,325 at June 30, 2003. As of September 30, 2003, amounts owing to officers of the Company stood at $71,110 compared to $40,241 at June 30, 2003. The amounts owed by our Company to its officers are non-interest bearing, unsecured and have no fixed terms of repayment.
As of September 30, 2003, our Company's total assets were $907,265. This compares with our Company's assets of $689,781 at June 30, 2002. The increase in the Company's total assets was attributable to the equity financing that our Company concluded in the latest period
Results of Operations
On the acquisition of all of the assets related to the C-Chip technology the Company discontinued its mineral exploration business and has allocated related expenses, totaling $602,606 to Loss from Discontinued Operations. Although we have shipped products in the quarter ended September 30, 2003, our Company has not recorded any revenue from its newly acquired technology. Although shipments of product have occurred and we have invoiced clients, our Company still records this as cost recoveries with a reduction in the respective expense in the statement of operations. As shipments of our first product, the Credit Manager, is ramping up, we expect to begin to account for actual revenue in the current quarter,
Our Company posted losses of $1,706,097 for the three months ending September 30, 2003, including $46,579 of expenses relating to stock based compensation and $1,418,451 relating to the discount on conversion of the Debenture held by Capex. Since inception on June 26, 2000, we have posted losses of $3,432,946, including $602,606 from discontinued operations. The principal component of the loss before discontinued operations is $650,000 of acquired in process research and development related to the acquisition of the C-Chip technology which was amortized immediately and the above mentioned discount on conversion of debt.
Critical Accounting Policies
The Company's discussion and analysis of its financial condition and results of operations are based upon the financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of financial statements require management to make estimates and judgments that affect the reported amounts of assets and liabilities, revenues and expenses and disclosures on the date of the financial statements. On an on-going basis, the Company evaluates its estimates, including, but not limited to, those related to revenue recognition. The Company uses authoritative pronouncements, historical experience and other assumptions as the basis for making judgments. Actual results could differ from those estimates.
ITEM 3. CONTROLS AND PROCEDURES
Quarterly evaluation of our disclosure controls and internal controls
Within the 90 days prior to the date of this quarterly report on Form 10-QSB, we evaluated the effectiveness of the design and operation of our "disclosure controls and procedures" (Disclosure Controls), and our "internal controls and procedures for financial reporting" (Internal Controls). This evaluation (the Controls Evaluation) was done under the supervision and with the participation of our management, including our chief executive officer (CEO) and chief financial officer (CFO). Our CEO performs the same functions as a principal executive officer and our CFO performs the same functions as a principal financial officer. Rules adopted by the SEC require that in this section of the quarterly report we present the conclusions of our CEO and our CFO about the effectiveness of our Disclosure Controls and Internal Controls based on and as of the date of the Controls Evaluation.
- 21 -
CEO and CFO certifications
Appearing immediately following the signatures section of this quarterly report there are two separate forms of "Certifications" of the CEO and the CFO. The first form of Certification is required in accord with Section 302 of the Sarbanes-Oxley Act of 2002 (the Section 302 Certification). This section of the quarterly report which you are currently reading is the information concerning the Controls Evaluation referred to in the Section 302 Certifications and this information should be read in conjunction with the Section 302 Certifications for a more complete understanding of the topics presented.
Disclosure controls and internal controls
Disclosure Controls are procedures that are designed with the objective of ensuring that information required to be disclosed in our reports filed under the Securities Exchange Act of 1934 (Exchange Act), such as this quarterly report, is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission's (SEC) rules and forms. Disclosure Controls are also designed with the objective of ensuring that such information is accumulated and communicated to our management, including the CEO and CFO, as appropriate to allow timely decisions regarding required disclosure. Internal Controls are procedures which are designed with the objective of providing reasonable assurance that (1) our transactions are properly authorized; (2) our assets are safeguarded against unauthorized or improper use; and (3) our transactions are properly recorded and reported, all to permit the preparation of our financial statements in conformity with generally accepted accounting p rinciples.
Limitations on the effectiveness of controls
Our management, including our CEO and CFO, confirm that the control systems are at the "reasonable assurance" level, however, management does not expect that our Disclosure Controls or our Internal Controls will prevent all error and all fraud as a control system. No matter how well conceived and operated, they cannot provide absolute assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within our company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. However, upon discovery that the controls are inadequate, they will be changed.
- 22 -
Scope of the controls evaluation
Our CEO/CFO evaluation of our Disclosure Controls and our Internal Controls included a review of the controls' objectives and design, the controls' implementation by us and the effect of the controls on the information generated for use in this quarterly report. In the course of the Controls Evaluation, we sought to identify data errors, controls problems or acts of fraud and to confirm that appropriate corrective action, including process improvements, were being undertaken. This type of evaluation will be done on a quarterly basis so that the conclusions concerning controls effectiveness can be reported in our Quarterly Reports on Form 10-QSB and Annual Report on Form 10-KSB. Our Internal Controls are also evaluated on an ongoing basis by our independent auditors in connection with their audit and review activities. The overall goals of these various evaluation activities are to monitor our Disclosure Controls and our Internal Controls and to make modifications as necessary; our intent in this regard is that the Disclosure Controls and the Internal Controls will be maintained as dynamic systems that change (including with improvements and corrections) as conditions warrant.
Among other matters, we sought in our evaluation to determine whether there were any "significant deficiencies" or "material weaknesses" in our Internal Controls, or whether we had identified any acts of fraud involving personnel who have a significant role in our Internal Controls. This information was important both for the Controls Evaluation generally and because items 5 and 6 in the Section 302 Certifications of the CEO and CFO require that the CEO and CFO disclose that information to our Board's Audit Committee and to our independent auditors and to report on related matters in this section of the quarterly report. In the professional auditing literature, "significant deficiencies" are referred to as "reportable conditions"; these are control issues that could have a significant adverse effect on the ability to record, process, summarize and report financial data in the financial statements. A "material weakness" is defined in the auditing literature as a particularly serious reportable condition wh ere the internal control does not reduce to a relatively low level the risk that misstatements caused by error or fraud may occur in amounts that would be material in relation to the financial statements and not be detected within a timely period by employees in the normal course of performing their assigned functions. We also sought to deal with other controls matters in the Controls Evaluation, and in each case if a problem was identified, we considered what revision, improvement and/or correction to make in accord with our on-going procedures.
In accord with SEC requirements, our CEO and CFO note that, since the date of the Controls Evaluation to the date of this Quarterly Report, there have been no significant changes in Internal Controls or in other factors that could significantly affect Internal Controls, including any corrective actions with regard to significant deficiencies and material weaknesses.
Conclusions
Based upon the Controls Evaluation, our CEO and CFO have concluded that, our Disclosure Controls are effective to ensure that material information relating to us and our subsidiary is made known to management, including our CEO and CFO, particularly during the period when our periodic reports are being prepared, and that our Internal Controls are effective to provide reasonable assurance that our financial statements are fairly presented in conformity with generally accepted accounting principles.
- 23 -
PART II
ITEM 2. CHANGES IN SECURITIES
(c)
The following are securities sold by us without registration during the period from July 1, 2003 to September 30, 2003:
On July 25, 2003, Capex Investments Limited converted an outstanding debenture to 3,910,120 restricted shares of common stock.
On August 22, 2003 we issued 250,000 restricted shares of common stock to Oleg Kharlanov in consideration of $137,500.
On August 26, 2003 we issued 70,000 restricted shares of common stock to VP Bank in consideration of $38,500.
On September 10, 2003, Capex Investments Limited converted an outstanding promissory note to 909,091 restricted shares of common stock.
On September 12, 2003 we issued 109,091 restricted shares of common stock to Oleg Kharlanov in consideration of $60,000.
On September 18, 2003 we issued 90,910 restricted shares of common stock to Oleg Kharlanov in consideration of $50,000.
On September 25, 2003 we issued 181,818 restricted shares of common stock to Prospect Fund L.P. in consideration of $100,000.
All of the foregoing transactions were exempt from registration under the Securities Act of 1933 (the "Act") pursuant to the exemptions available in section 4(2) of the Act or Reg. S promulgated under the Act.
- 24 -
ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K
| Exhibit No.
| Document
|
| 31.1 | Certification of Principal Executive Officer pursuant to Rule 13a-15(a) and Rule 15d-15(a), promulgated under the Securities Exchange Act of 1934, as amended |
| | |
| 31.2 | Certification of Principal Financial Officer pursuant to Rule 13a-15(a) and Rule 15d-15(a), promulgated under the Securities Exchange Act of 1934, as amended |
| | |
| 32.1 | Certification Pursuant To 18 U.S.C. Section 1350, As Adopted Pursuant To Section 906 Of The Sarbanes-Oxley Act of 2002 (Chief Executive Officer) |
| | |
| 32.2 | Certification Pursuant To 18 U.S.C. Section 1350, As Adopted Pursuant To Section 906 Of The Sarbanes-Oxley Act of 2002 (Chief Financial Officer) |
Reports on Form 8-K
The following reports on Form 8-K were filed during the quarter:
On July 16, 2003, we filed a Form 8-K reporting the following events:
On June 30, 2003, we entered into an agreement with Capex Investments to extend the due date of our promissory note in the amount of $500,000 from May 31, 2003 to December 31, 2003 or to the date of the closing of our private placement, which ever occurs first.
- 25 -
SIGNATURES
In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on this 18th day of November, 2003.
| C-CHIP TECHNOLOGIES CORPORATION (Registrant) |
|
BY: |
/s/ Stephane Solis |
| | Stephane Solis, President, Principal Executive Officer and a member of the Board of Directors. |
|
BY: |
/s/ Benjamin Leboe |
| | Benjamin Leboe, Principal Financial Officer |
- 26 -